A potential role for targeted therapy in a subset of metastasizing XXXX .

@entity1 @entity38077 @entity5 @entity470 @entity984 @entity4937 @entity189 @entity876 @entity3 @entity2467 @entity817 @entity10160 @entity1722
Metastasizing @entity189 are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target @entity5 -promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry ( @entity470 ( @entity470 ), @entity1722 , and @entity2467 ), @entity470 and @entity1722 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot   genotyping (testing for recurrent mutations in 15 @entity5 genes including @entity817 , @entity470 , @entity984 , @entity10160 , and @entity876 ) on @entity5 and corresponding @entity3 of 14 metastasizing @entity189 (three apocrine, six eccrine, two hidradenocarcinomas, two @entity38077 , and one @entity4937 ). @entity3 to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 @entity1 (5 months to 8   years) with 1 died of widespread @entity3 . Although @entity470 overexpression was a prevalent feature in this cohort, seen in 7/11 (64%) @entity5 and 10/14 (71%) @entity3 ; FISH for @entity470 gene amplification was negative in 9 tested @entity5 and 12 @entity3 . FISH of the one @entity5 and three @entity3 with 2+ @entity1722 overexpression revealed a low level of @entity1722 gene amplification in one @entity189 and corresponding @entity3 . @entity2467 expression was seen only in rare cases. @entity10160 (2/12, 17%) and @entity876 (3/12, 25%) mutations were detected in two (one hidradenocarcinoma, @entity38077 ) and three (one eccrine, one hidradenocarcinoma, and one @entity4937 ) cases, respectively. The role of @entity470 inhibitor therapy in metastasizing @entity189 with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of @entity189 with @entity3 .
